Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
~ Delivered 8% sales growth and 21% adjusted EPS growth in full year 2025 ~ ~ 2026 Outlook maintains midpoint of sales growth and high end of adjusted EPS growth from October outlook ~~ Continue to...
-
CHASKA, Minn., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”),...
-
Dublin, Feb. 03, 2026 (GLOBE NEWSWIRE) -- The "Pharmaceutical Contract Development and Manufacturing Organization (CDMO) - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts...
-
Halo Pharma to become a stand-alone Drug Product CDMO.
-
Acquisition adds further specialist biostatistics, data management, and medical writing expertise to Evestia Clinical’s full-service offering and strengthens its presence in Germany and across Europe ...
-
Dublin, Jan. 23, 2026 (GLOBE NEWSWIRE) -- The "mRNA Therapeutics Contract Development & Manufacturing (CDMO) Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031"...
-
Dublin, Jan. 22, 2026 (GLOBE NEWSWIRE) -- The "Small Molecule Innovator CDMO Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031" has been added to ...
-
Wayne, PA, Jan. 21, 2026 (GLOBE NEWSWIRE) -- TekniPlex Healthcare, which utilizes advanced materials science expertise to help deliver better patient outcomes, will showcase its interventional and...
-
Dublin, Jan. 19, 2026 (GLOBE NEWSWIRE) -- The "Oligonucleotide CDMO Market Size, Share & Trends Analysis Report by Service (Contract Development, Contract Manufacturing), Type (Antisense...
-
CHASKA, Minn., Jan. 16, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”) a fully integrated contract development and manufacturing organization (“CDMO”), today...